Varespladib methyl clinical trials
Also written A-002 and LY333013.
How each study uses varespladib methyl is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2007 | 3 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 1
Anthera Pharmaceuticals (6) · Ophirex, Inc. (2) · University Health Network, Toronto (1)
Studies
Open first, then newest update. How each study uses varespladib methyl is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Broad-spectrum Rapid Antidote: Varespladib Oral for SnakebiteCompletedPhase 2Ophirex, Inc.NCT04996264Written as Varespladib Methyl
- Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)CompletedPhase 2Ophirex, Inc.NCT05717062Written as varespladib-methyl- oral form
- FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary SyndromesCompletedPhase 2Anthera PharmaceuticalsNCT00743925Written as Varespladib Methyl (A-002)
- VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary SyndromeTerminatedPhase 3Anthera PharmaceuticalsNCT01130246Written as A-002, varespladib methyl
- A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal FunctionTerminatedPhase 1Anthera PharmaceuticalsNCT01359579Written as varespladib methyl
- Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male SubjectsCompletedPhase 1Anthera PharmaceuticalsNCT01359605Written as varespladib methyl
- PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery DiseaseCompletedPhase 2Anthera PharmaceuticalsNCT00455546Written as A-002
- sPLA2 Inhibition to Decrease Enzyme Release After PCI TrialCompletedPhase 2University Health Network, TorontoNCT00533039Written as Varespladib (A-002)
- PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery DiseaseCompletedPhase 2Anthera PharmaceuticalsNCT00525954Written as A-002
Codes
What other systems call varespladib methyl · ClinicalTrials.gg INT005517
- MeSH (NLM) C545088varespladib methylConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0NB98NBX3DVARESPLADIB METHYLConfirmed FDA, NLM, Wikidata
- Wikidata Q7915615varespladib methylConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152833Varespladib MethylOne source FDA
- DrugBank DB05737One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545088 | varespladib methyl | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0NB98NBX3D | VARESPLADIB METHYL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7915615 | varespladib methyl | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152833 | Varespladib Methyl | One source FDA |
| DrugBank | DB05737 | — | One source Wikidata |
Also registered as entacingene turiparvovec (UNII LG7B4QT3EN).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.